Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

3.80
-0.0200-0.52%
Post-market: 3.810.0085+0.22%19:57 EDT
Volume:11.01M
Turnover:41.71M
Market Cap:1.57B
PE:-3.47
High:3.87
Open:3.82
Low:3.71
Close:3.82
52wk High:5.63
52wk Low:1.64
Shares:411.96M
Float Shares:339.00M
Volume Ratio:0.48
T/O Rate:3.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0941
EPS(LYR):-1.0941
ROE:-55.50%
ROA:-27.30%
PB:2.24
PE(LYR):-3.47

Loading ...

Iovance Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Apr 11

Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE) and Iovance Biotherapeutics (IOVA)

TIPRANKS
·
Apr 11

Replimune CRL positive for Iovance in near-term, says Chardan

TIPRANKS
·
Apr 11

Unusually active option classes on open April 10th

TIPRANKS
·
Apr 10

A Look At Iovance Biotherapeutics (IOVA) Valuation After Strong Amtagvi Data And Growing Pipeline Momentum

Simply Wall St.
·
Apr 09

Mizuho Securities Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)

TIPRANKS
·
Mar 30

Is Iovance Biotherapeutics (IOVA) Offering A Compelling Opportunity After Recent Price Swings?

Simply Wall St.
·
Mar 25

A Look At Iovance Biotherapeutics (IOVA) Valuation After Pipeline And Regulatory Updates At Barclays Healthcare Conference

Simply Wall St.
·
Mar 22

Iovance Biotherapeutics grants 3,400 inducement stock options at USD 3.87 exercise price

Reuters
·
Mar 21

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 21

Iovance director Wendy Yarno to retire from board in June 2026

Reuters
·
Mar 21

Iovance Biotherapeutics (IOVA) Is Up 42.7% After Positive Lifileucel Sarcoma Data And New Trial Plan

Simply Wall St.
·
Mar 11

A Look At Iovance Biotherapeutics (IOVA) Valuation After Sharp Recent Share Price Momentum

Simply Wall St.
·
Mar 09

Iovance Biotherapeutics call volume above normal and directionally bullish

TIPRANKS
·
Mar 07

What's Going On With Iovance Biotherapeutics Stock On Friday?

Benzinga_recent_news
·
Mar 07

UBS Adjusts Iovance Biotherapeutics Price Target to $4 From $2, Maintains Neutral Rating

MT Newswires Live
·
Mar 05

Iovance Biotherapeutics Is Maintained at Neutral by UBS

Dow Jones
·
Mar 05

Iovance Biotherapeutics Inc : UBS Raises Target Price to $4 From $2

THOMSON REUTERS
·
Mar 05

Iovance Biotherapeutics price target raised to $4 from $2 at UBS

TIPRANKS
·
Mar 05

Iovance Biotherapeutics Raised to Market Outperform From Market Perform by Citizens

Dow Jones
·
Mar 03